For now, it is important to incorporate what is currently known about CYP3A4, CYP3A5, CYP2C8, and ABCB1 into the assessment of a patient when the mTOR pathway is a desired target in treating a tumor. This evidence concerns the gene CYP3A5 and neoplasm.